Haemonetics (NYSE:HAE) Receives “Strong-Buy” Rating from Raymond James

Raymond James reiterated their strong-buy rating on shares of Haemonetics (NYSE:HAE – Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $115.00 price target on the medical instruments supplier’s stock, down from their prior price target of $120.00. HAE has been the topic of a number of other research […]

Leave a Reply

Your email address will not be published.

Previous post American Capital Advisory LLC Acquires 12,049 Shares of Etsy, Inc. (NASDAQ:ETSY)
Next post Protagonist Therapeutics (NASDAQ:PTGX) Given Market Outperform Rating at JMP Securities